Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Protirelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHR known ✓ | P34981 | 6/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Protirelin SCHEMBL33419 | 0.95 | TRHR (1.00) | TRHR | |
| Protirelin SCHEMBL16091769 | 0.95 | TRHR (1.00) | TRHR | |
| Protirelin SCHEMBL10087946 | 0.95 | TRHR (1.00) | TRHR | |
| Protirelin SCHEMBL10087855 | 0.95 | TRHR (1.00) | TRHR | |
| Protirelin SCHEMBL4406163 | 0.94 | TRHR (0.93) | TRHR | |
| SCHEMBL29539733 | 0.89 | TRHR (0.85) | TRHR | |
| Azetirelin SCHEMBL195158 | 0.87 | TRHR (0.85) | TRHR | |
| Protirelin SCHEMBL11309963 | 0.87 | TRHR (0.84) | TRHR | |
| SCHEMBL16088505 | 0.87 | TRHR (0.84) | TRHR | |
| SCHEMBL16072685 | 0.87 | TRHR (0.84) | TRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-3115044-B1 | PATCH PREPARATION | TEIKOKU SEIYAKU KK (JP) | 2024-07-31 | — | — | EP | disclosed |
| EP-3212688-B1 | THERMOPLASTIC POLYURETHANE FILM FOR DELIVERY OF ACTIVE AGENTS TO SKIN SURFACES | LUBRIZOL ADVANCED MAT INC (US) | 2022-04-13 | — | — | EP | disclosed |
| US-10905646-B2 | Thermoplastic polyurethane film for delivery of active agents to skin surfaces | LUBRIZOL ADVANCED MATERIALS, INC. | 2021-02-02 | — | — | US | disclosed |
| US-20200297549-A1 | FLEXIBLE HOLLOW STRUCTURE, ADHESIVE TAPE, AND FUNCTIONAL ADHESIVE SHEET | RICOH COMPANY, LTD. (JP) | 2020-09-24 | — | — | US | disclosed |
| US-10695335-B2 | Patch preparation | TEIKOKU SEIYAKU CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| EP-3075738-B1 | GLYCYRRHETINIC ACID DERIVATIVE AND USE THEREOF | INI CORP (JP) | 2019-02-13 | — | — | EP | disclosed |
| US-20180311358-A1 | THERMOFORMABLE DUAL NETWORK HYDROGEL COMPOSITIONS | LUBRIZOL ADVANCED MATERIALS, INC. | 2018-11-01 | — | — | US | disclosed |
| EP-3371238-A1 | THERMOFORMABLE DUAL NETWORK HYDROGEL COMPOSITIONS | Lubrizol Advanced Materials, Inc. (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-2269593-B1 | TRANSDERMALLY ABSORBABLE PREPARATION | TEIKOKU SEIYAKU KK (JP) | 2018-05-02 | — | — | EP | disclosed |
| EP-1155701-A1 | ENTERAL SORBEFACIENTS | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2001-11-21 | — | — | EP | disclosed |
| EP-1084704-A1 | REMEDIES FOR SPINOCEREBELLAR ATAXIA AND COMPOSITIONS FOR TREATING SPINOCEREBELLAR ATAXIA | MEIJI SEIKA KAISHA LTD. (JP) | 2001-03-21 | — | — | EP | disclosed |
| EP-0665009-B1 | CRYSTALLINE CONDITION DISLOCATING METHOD | NIPPON SHINYAKU CO LTD (JP) | 2000-02-16 | — | — | EP | disclosed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| US-5789375-A | Pernasal composition and pernasal preparation containing the same | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1998-08-04 | — | — | US | disclosed |
| EP-0724885-A1 | PERNASAL COMPOSITION AND PERNASAL PREPARATION CONTAINING THE SAME | Hisamitsu Pharmaceutical Co., Inc. (JP) | 1996-08-07 | — | — | EP | disclosed |
| EP-0665009-A1 | CRYSTALLINE CONDITION DISLOCATING METHOD | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-08-02 | — | — | EP | disclosed |
| EP-0107941-B1 | SOFT BUCCAL | Takeda Chemical Industries, Ltd. (JP) | 1987-12-23 | — | — | EP | disclosed |
| US-4572832-A | MEDICATION ABSORBED THROUGH MUCOUS MEMBRANE; SLOW RELEASE | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1986-02-25 | — | — | US | disclosed |
| EP-0107941-A1 | Soft buccal | Takeda Chemical Industries, Ltd. (JP) | 1984-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10905646-B2 | Thermoplastic polyurethane film for delivery of active agents to skin surfaces | DNER, CUTA, PUF60 | TRHR 1877/4885 |
| US-20180311358-A1 | THERMOFORMABLE DUAL NETWORK HYDROGEL COMPOSITIONS | HSF1, DUOX2, HSPA2 | TRHR 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.